This session will look at a number of simple steps that can be taken to implement a healthy risk management framework within the core of a healthcare business – aimed at strengthening team culture and behavioural norms.

Risk is inherent in any business – from the disclosure of sensitive information, legal & regulatory compliance through to the handling of emergency product recall or supply issues. Risk can sometimes be eliminated but in all cases can be minimised through behavioural practice. This session will give examples of pressure points such as the disclosure of sensitive information, regulatory investigations and dealing with the communication of serious safety issues (patient or product safety) and product recalls – all of which may have significant reputational exposure alongside legal risk. We will cover the legal topics of confidentiality, privilege, pharmacovigilance and issue management governance.

You may also like

Patent strategies for personalised medicine and medical devices

Tuesday 16th March

This session will cover an overview of personalised medicine, UK and European patent law relating to patentability of biotechnology inventions and case studies identifying considerations for developing IP strategies to support the commercialisation of a personalised medicine or a personalised medical device.

The power of bioinformatics: a focus on capturing bioinformatics innovation as part of an IP strategy

Thursday 18th March

We will look at patent trends in bioinformatics along with some real life case studies in order to see how companies have successfully protected bioinformatics innovations in areas including computational neuroscience, DNA Sequencing and remote healthcare monitoring.

Motivating big pharma to embrace emerging technology: it’s not always about the small molecule

Tuesday 2nd March

The discussion will look at the advantages and disadvantages of engaging with Big Pharma, and then look at what can attract Big Pharma to new territories. Our conclusions will be used to reflect broadly on what this may mean for the microbiome field.